HHS

FOA# Topic/Title Budget Deadline
NOT-MH-24-110 Notice of Special Interest (NOSI): SBIR/STTR Program Priorities to Bridge Gaps in Advancing the NIMH Mission N/A January 6, 2027
NOT-MH-24-120 Notice of Special Interest (NOSI): SBIR/STTR High-Priority Areas for Digital Mental Health Innovations N/A January 6, 2027
PAR-24-066 NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required) $2,000,000 September 23, 2026
PAS-22-196 Advancing Research on Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) $275,766 Phase I $1,838,436 Phase II September 6, 2025
RFA-DA-23-021 Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 – Clinical Trial Optional) $320K,000 (Phase I); $2,500,000 (Phase II) February 15, 2025
NOT-NS-22-017 Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) varies by mechanism January 7, 2025
PA-21-345 Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) varies by mechanism September 10, 2024
NOT-DE-21-012 Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed) $259,613 for Phase I awards and $1,730,751 for Phase II awards September 5, 2025
PAR-21-282 Blueprint Medtech: Small Business Translator (U44 – Clinical Trial Optional) $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II June 21, 2024
PAR-21-226 Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed) $259,613 Phase I
$1,730,751 Phase II		 September 6, 2024
PAR-21-225 Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed) $259,613 Phase I
$1,730,751 Phase II		 September 6, 2024
PAR-20-128 SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed) $250,000 – $300,000 Standard SBIR dates
PAR-20-129 SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) varies by IC Standard SBIR dates
PAR-20-130 SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) varies by IC Standard SBIR dates
PA-20-260 PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) $256,580 Phase I
$1,710,531 Phase II		 Standard SBIR dates
PA-20-261 PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) $256,580 Phase I
$1,710,531 Phase II		 Standard SBIR dates
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) $256,580 Phase I
$1,710,531 Phase II		 Standard SBIR dates
PA-20-265 PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) $256,580 Phase I
$1,710,531 Phase II		 Standard SBIR dates
NOT-MH-20-013 Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment
NOT-MH-20-020 Notice of Special Interest: Stigma or Other Social Determinants of Health (SDOH) in HIV Prevention and Treatment
NOT-MH-20-023 Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum
NOT-MH-20-024 Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets
NOT-MH-20-035 Notice of Special Interest: Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults
PAR-18-801 Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 – Clinical Trial Optional) $300,000 Phase I
$2,000,000 Phase II		 Standard Dates
PAR-20-109 Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed) Standard Phase I, II budgets Standard SBIR/STTR dates
PAR-20-098 Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed) Standard Phase I, II budgets Standard SBIR/STTR dates

DoE

FOA# TOPIC/TITLE BUDGET DEADLINE
Cradle-to-Commerce (C2C) N/A December 20, 2024
CDMRP Ovarian Cancer Research Program (OCRP) $300,000-2,000,000

Multiple Agencies

FOA# TOPIC/TITLE BUDGET DEADLINE
Sensor Technology for the 21st Century varies varies

Disclaimer: EGC is not endorsed by the United States Department of Energy or any of its employees, contractors, or subcontractors.